Since the approval of Soliris® in 2007, an anti-C5 antibody, the field of complement drug discovery has gained significant attention. Currently, nine complement therapeutics are commercially available, while around 190 molecules are under development for various disease indications. Some of the complement therapeutics, namely Berinert®, Cinryze®, ORLADEYO®, Ruconest® and TAKHZYRO® were approved for the treatment of hereditary angioedema, by the US FDA and the EMA. These next generation therapeutics inhibit complement activation, thereby reducing tissue inflammation and dampening the adaptive immune response to foreign and tissue antigens.
Complement Therapeutics – Current Market Landscape
Currently, over 45 companies worldwide are actively engaged in the development of next generation complement therapeutics with enhanced efficacy. The market is characterized by a mix of well-established and small firms.
Want additional details on the pipeline?
The pipeline features more than 190 next generation complement therapeutics that are either marketed / are currently being evaluated across different phases of development. Majority of these are biologics and are being developed for the treatment of different disease conditions, including dermatological, genetic, hematological and vascular, immunological and inflammatory, infectious, neurological, ophthalmic, renal disorders.
Broad Clinical Trial Landscape
Till date, more than 870 clinical studies evaluating various complement-targeted therapeutics and involving nearly 2,430,000 patients enrolled across different centers / hospitals, have been initiated worldwide.
Published Scientific Literature: Indicative of the Ongoing pace of Research in this Field
Over the years, there has been a gradual increase in the number of publications related to next generation complement therapeutics. Majority of the publications were focused on therapeutics being investigated for the treatment of Hereditary Angioedema; such articles account for more than 40% of the total number of publications.
High Number of Patents are Suggestive of the Widespread Research in this Domain
Several industry and non-industry players are involved in the development of next generation complement therapeutics. The field has seen a significant rise in the number of patents over the past few years, with AbbVie leading the way in terms of the total number of patents filed / granted.
Billions of Dollars Invested in Venture Capital Funding
The rising interest of investors within this upcoming segment is evident from the fact that nearly USD 1.1 billion was invested in venture capital funding by various industry and non-industry players, since 2017.
Future Evolution of Complement Therapeutics Market
With the rising demand for novel therapeutic modalities, the next generation therapeutics market is anticipated to grow at an annualized rate of more than 15% between 2022 and 2035.
Owing to the fact that the complement system is a multidimensional innate immune surveillance system, more novel therapeutic targets are likely to be discovered in the future, with the active involvement of big pharma players as well as new pharma entrants. Further, with the encouraging clinical research efforts and broadening of disease focus, the complement inhibitors market is poised to witness steady growth over the coming years.
For more details, you can also download the SAMPLE REPORT on complement therapeutics by Roots Analysis.